NYSE:CBM - Cambrex Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $38.27 -0.07 (-0.18 %) (As of 02/20/2019 04:00 PM ET)Previous Close$38.34Today's Range$37.94 - $39.1852-Week Range$33.80 - $69.43Volume452,609 shsAverage Volume463,283 shsMarket Capitalization$1.29 billionP/E Ratio13.82Dividend YieldN/ABeta2.45 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey. Receive CBM News and Ratings via Email Sign-up to receive the latest news and ratings for CBM and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryLife Sciences Tools & Services SectorMedical Current SymbolNYSE:CBM Previous Symbol CUSIP13201110 Webwww.cambrex.com Phone201-804-3000Debt Debt-to-Equity Ratio0.46 Current Ratio3.93 Quick Ratio2.86Price-To-Earnings Trailing P/E Ratio13.82 Forward P/E Ratio12.89 P/E Growth1.27 Sales & Book Value Annual Sales$532.09 million Price / Sales2.42 Cash Flow$3.9658 per share Price / Cash Flow9.65 Book Value$19.45 per share Price / Book1.97Profitability EPS (Most Recent Fiscal Year)$2.77 Net Income$92.41 million Net Margins17.37% Return on Equity14.74% Return on Assets9.10%Miscellaneous Employees1,732 Outstanding Shares33,609,000Market Cap$1.29 billion OptionableOptionable Cambrex (NYSE:CBM) Frequently Asked Questions What is Cambrex's stock symbol? Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM." How were Cambrex's earnings last quarter? Cambrex Co. (NYSE:CBM) posted its quarterly earnings results on Wednesday, February, 13th. The biotechnology company reported $1.44 EPS for the quarter, beating the Zacks' consensus estimate of $1.32 by $0.12. The biotechnology company earned $212.30 million during the quarter, compared to analyst estimates of $182.49 million. Cambrex had a net margin of 17.37% and a return on equity of 14.74%. The firm's revenue was up 16.5% compared to the same quarter last year. During the same period in the prior year, the business posted $1.26 EPS. View Cambrex's Earnings History. When is Cambrex's next earnings date? Cambrex is scheduled to release their next quarterly earnings announcement on Thursday, May 2nd 2019. View Earnings Estimates for Cambrex. What guidance has Cambrex issued on next quarter's earnings? Cambrex issued an update on its FY19 earnings guidance on Wednesday, February, 13th. The company provided EPS guidance of $1.87-2.09 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.18. Cambrex also updated its FY 2019 guidance to $1.87-2.09 EPS. What price target have analysts set for CBM? 4 equities research analysts have issued 12 month target prices for Cambrex's shares. Their forecasts range from $45.00 to $75.50. On average, they anticipate Cambrex's share price to reach $61.1667 in the next year. This suggests a possible upside of 59.8% from the stock's current price. View Analyst Price Targets for Cambrex. What is the consensus analysts' recommendation for Cambrex? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cambrex in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cambrex. Has Cambrex been receiving favorable news coverage? Media stories about CBM stock have been trending neutral on Wednesday, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cambrex earned a daily sentiment score of 0.3 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the company's share price in the next several days. Who are some of Cambrex's key competitors? Some companies that are related to Cambrex include Array Biopharma (ARRY), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), Taro Pharmaceutical Industries (TARO), TESARO (TSRO), Amneal Pharmaceuticals (AMRX), Horizon Pharma (HZNP), Agios Pharmaceuticals (AGIO), Evotec (EVTCY), HUTCHISON CHINA/S (HCM), Emergent Biosolutions (EBS), Blueprint Medicines (BPMC), Intercept Pharmaceuticals (ICPT), Ascendis Pharma A/S (ASND) and ACADIA Pharmaceuticals (ACAD). Who are Cambrex's key executives? Cambrex's management team includes the folowing people: Mr. Steven M. Klosk, Pres, CEO & Director (Age 62)Mr. Gregory P. Sargen, Exec. VP of Corp. Devel. & Strategy and CFO (Age 53)Mr. Shawn P. Cavanagh, Exec. VP & COO (Age 53)Ms. Samantha M. Hanley, VP, Gen. Counsel & Corp. Sec. (Age 41)Mr. James G. Farrell, VP & Corp. Controller (Age 52) Who are Cambrex's major shareholders? Cambrex's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (14.56%), Bank of New York Mellon Corp (4.93%), Mackenzie Financial Corp (4.43%), Dimensional Fund Advisors LP (4.20%), American Capital Management Inc. (1.99%) and Ranger Investment Management L.P. (1.96%). Company insiders that own Cambrex stock include Gregory Sargen, Ilan Kaufthal, Leon J Hendrix Jr, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and Tom George Vadaketh. View Institutional Ownership Trends for Cambrex. Which institutional investors are selling Cambrex stock? CBM stock was sold by a variety of institutional investors in the last quarter, including Fiera Capital Corp, Acadian Asset Management LLC, Investment Counselors of Maryland LLC, LSV Asset Management, American Capital Management Inc., New York State Common Retirement Fund, Barclays PLC and Portolan Capital Management LLC. Company insiders that have sold Cambrex company stock in the last year include Gregory Sargen, Ilan Kaufthal, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and Tom George Vadaketh. View Insider Buying and Selling for Cambrex. Which institutional investors are buying Cambrex stock? CBM stock was purchased by a variety of institutional investors in the last quarter, including Mackenzie Financial Corp, Copper Rock Capital Partners LLC, BlackRock Inc., Bank of New York Mellon Corp, Epoch Investment Partners Inc., Monarch Partners Asset Management LLC, Peregrine Capital Management LLC and Bank of America Corp DE. View Insider Buying and Selling for Cambrex. How do I buy shares of Cambrex? Shares of CBM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Cambrex's stock price today? One share of CBM stock can currently be purchased for approximately $38.27. How big of a company is Cambrex? Cambrex has a market capitalization of $1.29 billion and generates $532.09 million in revenue each year. The biotechnology company earns $92.41 million in net income (profit) each year or $2.77 on an earnings per share basis. Cambrex employs 1,732 workers across the globe. What is Cambrex's official website? The official website for Cambrex is http://www.cambrex.com. How can I contact Cambrex? Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected] MarketBeat Community Rating for Cambrex (NYSE CBM)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 233 (Vote Outperform)Underperform Votes: 216 (Vote Underperform)Total Votes: 449MarketBeat's community ratings are surveys of what our community members think about Cambrex and other stocks. Vote "Outperform" if you believe CBM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/20/2019 by MarketBeat.com StaffFeatured Article: What impact do institutional investors have on markets?